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Abstract NOVOCART® Disk plus, an autologous cell
compound for autologous disk chondrocyte transplanta-
tion, was developed to reduce the degenerative sequel after
lumbar disk surgery or to prophylactically avoid degenera-
tion in adjacent disks, if present. The NDisc trial is an on-
going multi-center, randomized study with a sequential
phase I study within the combined phase I/II trial with close
monitoring of tolerability and safety. Twenty-four adult pa-
tients were randomized and treated with the investigational
medicinal product NDisc plus or the carrier material only.
Rates of adverse events in Phase I of this trial were compa-
rable with those expected in the early time course after
elective disk surgery. There was one reherniation 7 months
after transplantation, which corresponds to an expected
reherniation rate. Immunological markers like CRP and
IL-6 were not significantly elevated and there were no im-
aging abnormalities. No indications of harmful material ex-
trusion or immunological consequences due to the investi-
gational medicinal product NDplus were observed.
Therefore, the study appears to be safe and feasible.
Safety analyses of Phase I of this trial indicate a relatively
low risk considering the benefits that patients with debili-
tating degenerative disk disease may gain.
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Introduction
Intervertebral disk degeneration (IVDD) is emphasized as an
important cause of low back pain (LBP) [1]. Current treatment
strategies are aggressive removal of the pathological disk or
spondylodesis that do not address options of restoring structural
or biological deteriorations of the intervertebral disk (IVD) as
the underlying problem. Therefore, disk repair procedures are
of interest to spine surgeons, because they offer a less invasive
and biological alternative to lumbar fusion in an attempt to
obviate LBP associated with IVDD earlier in the degenerative
cascade. Advances in molecular biology are now encouraging
innovative biological repair strategies. Different treatment mo-
dalities in vivo and in vitro include the administration of growth
factors, the application of autologous or allogenic cells, gene
therapeutic approaches, in situ therapy and the introduction of
biomaterials, or a combination thereof [2–7]. Especially, rein-
sertion of autologous nucleus pulpous cells or stem cells delays
degeneration in experimental in vivo or in vitro models of disk
degeneration [8–10]. In humans, the IVD potentially be
repaired after a herniation by transplanting the patient’s disk
chondrocyte. According to this method, which is called the
autologous disk-derived chondrocyte transplantation (ADCT),
the disk tissue which herniated through the annulus fibrosus is
removed at an initial surgical intervention. The chondrocytes
are then enzymatically isolated, expanded in vitro and the sus-
pension is reinjected into the damaged IVD [11].
Transplanted cultivated cells have to survive in a harsh
environment in the disk space with low nutrients and a high
amount of pro-inflammatory cytokines [12]. Therefore,
NOVOCART® Disk plus (NDplus) consists of a hydrogel
with anti-inflammatory, anti-angiogenic, anti-osteogenic
properties, and autologous disk cells for ADCT. This bioma-
terial is able to achieve a positive milieu conditioning of the
previously damaged intervertebral disk, and thus, is intended
to increase the survival rate and regeneration capability of the
transplanted cells. Furthermore, the liquid biomaterial poly-
merizes after being injected, which should improve the
cells’adherence.
NDplus was developed to provide rehydration and biolog-
ical integrity of degenerative lumbar disks to prevent second-
ary diseases such as osteochondrosis, recurrent lumbar disk
herniation, or segmental instability. In this phase-I/II study,
NDplus is being investigated for its clinical applicability, safe-
ty, and efficacy in the repair of herniated, nucleotomized disks,
and of adjacent degenerated disks, if present. To date, autolo-
gous disk chondrocytes have not been transplanted into de-
generative disks without previous disk herniation. This is pos-
sible in the presented study by injection of autologous cells
not only in the nucleotomized, but also in the adjacent
degenerated disks. As such, this is the first study to investigate
a therapeutic as well as a prophylactic approach to treat de-
generative disks of the lumbar spine.
The objective of phase I was to develop a safety pro-
file. This study further aims at developing and validating
known and new biologic markers for the quality and clin-
ical efficacy of the product as requested in the context of
identity, purity, and potency characteristics of the
medicinal/investigational product.
Clinical material and methods
Trial description
The NDisc study is a non-confirmatory, prospective, multi-
center, unmasked, randomized study with two phases aimed
at gathering preliminary clinical information on NDisc plus
and NDisc basic used in the repair of herniated disks. The
objectives of Phase I were to develop a safety profile and to
evaluate feasibility of NDplus. This report presents data from
Phase I up to 6 weeks after transplantation (Visit 4). Eligible
patients underwent baseline assessments, sequestrectomy, and
postoperative assessment of Visit 2. After this initial surgery,
all patients were randomized with a 1:1 allocation ratio to
either NDplus ADCTor NDbasic. Patients with a lumbar disk
herniation were classified according to the presence (ADD) or
absence (HD) of a degenerative disk at the adjacent level by
the investigators of the center. At Visit 3, patients underwent
pre-implantation assessments, transplantation and post-
transplantation assessments. A follow-up was performed at
Visit 4. The visit plan is shown in Table 1 in more detail.
Clinical investigation population
Twenty-four patients with a single-level lumbar herniated disk
were recruited consecutively in three different centers. The N-
Disc trial aimed to include patients with symptomatic lumbar
disk herniation who failed adequate conservative or interven-
tional treatment approaches in accordance with the guidelines
of the German Society of Neurosurgery and the German
Society of Orthopedics and Orthopedic Surgery.
Additionally, an MRI determined disk herniation at the treat-
ment level needed to correlate with the primary symptoms. To
minimize confounding, patients with significant comorbidities
were excluded from the study. Further inclusion criteria need-
ed to be met: (1) no previous lumbar spine surgery; (2) age
between 18 to 60 years; (3) proficient enough in the German
language to understand the study; (4) no magnetic resonance
imaging (MRI) documented associated lumbar disease such as
lumbar spinal stenosis, spondylolisthesis, or fracture. If pa-
tients showed an extensive damage of the annulus fibrosus
intraoperatively that may subsequently pose a significant
greater risk of recurrence or non-containment of the injected
material, they were excluded from the trial and randomization
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was not carried out. Written informed consent has been ob-
tained from each patient.
Assessments and laboratory values
Overall patient disposition and demographics, neurological,
and functional status were documented. Serology of HIV, hep-
atitis, and Treponema pallidumwere determined preoperative-
ly. Laboratory values such as interleukine-6 (IL-6) and C-
reactive protein (CRP) as safety parameters were evaluated.
All laboratory values were classified as normal or abnormal
according to the laboratories normal ranges. Systolic and dia-
stolic blood pressure and pulse rate as vital signs were
assessed. Adverse events (AE) and serious adverse events
(SAE) were documented. The analysis of adverse events
was focused on treatment emergent adverse events (TEAE).
A TEAE or TESAE is any AE or SAE that occurs during or
after implant. Frequency and percentage of TEAEs were sum-
marized according to the primary system organ class and pre-
ferred term and tabulated by treatment group.
Magnetic resonance imaging
Preoperative MRI of the lumbar spine was performed in a
standardized fashion on a 1.5-Tesla MRI scanner. The proto-
cols included T1- und T2-weighted turbo spin echo sequences
in sagittal and transversal planes, a sagittal STIR sequence, a
sagittal thin slice double echo volumetry sequence, and a sag-
ittal spin echo T2 multi-echo relaxometry sequence, addition-
ally. Numerical and comparative measurements in disk height,
volumetry, and T2 relaxations times of index and adjacent
disks and categorial evaluation such as degeneration scale,
and the presence or absence of stenosis were determined by
MRI. Osteochondrosis was graded by Modic changes [13].
The sequences were time optimized to improve patient’s ac-
ceptance and enable integrability of study protocols in the
local MRI schedules. Furthermore, an external institution
(MEDIRI—medical imaging research institute, Heidelberg,
Germany) adapted the protocol to the local scanners to arrange
image data comparability between the different study centers.
Additionally, the institution trained local radiographers in
standardized performance and engineered a software for cen-
tral image processing and analysis. All images were read by an
independent radiologist with high-level experience in spine
imaging, blinded to patients and time of image acquisition.
Trial organization, registration, and ethical aspects
The NDisc trial is an ongoing study of which Phase I safety
results are presented here. Ethics approval was attained in
G e rm a n y a t t h e N a t i o n a l P h y s i c i a n B o a r d ,
BLandesärztekammer^ Sachsen-Anhalt and in Austria at
the committee of the Medical University Innsbruck.
Furthermore, the clinical trial approval was obtained at
the Paul-Ehrlich-Institute (Langen, Germany) and the
Austrian Agency for Health and Food Safety (Vienna,
Austria). The study complies with the World Medical
Association Declaration of Helsinki Ethical Principles for
Medical Research Involving Human Subjects, Good
Clinical Practice (GCP), national pharmaceutical acts in
the participating countries Austria and Germany, and
European guidelines for the conduct of clinical trials with
medicinal products for human use. The trial is initiated and
sponsored by TETEC Ag (B|Braun Aesculap AG shared
company, Reutlingen, Germany), which is responsible for
management and registration (EudraCT No: 2010-023830-
22, ID NCT01640457). CenTrial GmbH (Tuebingen,
Germany) is responsible for clinical trial submission, inde-
pendent clinical monitoring, and pharmacovigilance.
Mediri GmbH (Heidelberg, Germany) as a core imaging
lab is responsible for the development of MRI protocols,
data storage, and analyses. Laboratory values are investi-
gated centrally by Synlab Services GmbH (Synlab MVZ,
Leinfelden-Echterdingen, Germany). Accovion GmbH
(Eschborn, Germany) is responsible for data management,
biometrics, and medial writing. Quality audits were per-
formed routinely by the Ministry of Health.
Investigational medicinal product
NDisc plus is used for ADCT. NDisc plus is an injectable, in
situ polymerizing gel initially consisting of two separate com-
ponents. Component A is a liquid matrix composed of the cell
culture medium, modified albumin, and hyaluronic acid.
Component A also contains autologous inter-vertebral disk
cells dissolved in cell culture medium supplemented with hu-
man serum, chondroitin sulfate, insulin, BMP-2, and ascor-
bate. Component B is a solution containing bis thio-
polyethylene glycol. Component A and B polymerize in situ
using a dedicated application system (special dual-chamber
syringe) to form the desired hydrogel. NDisc basic is used as
control in the NDisc study. In NDisc basic component A is a
liquid matrix composed of cell culture medium, modified al-
bumin, and hyaluronic acid, the cell suspension is replaced by
an aliquot of cell culture medium without additives.
Component B is not modified [14].
Sequestrectomy
Surgery was performed by two trial-designated surgeons un-
der general endotracheal anesthesia with the assistance of an
operating microscope while the patient was in a prone posi-
tion. Depending on the location of disk herniation, the spinal
canal harboring the sequestrated disk material was exposed
either by a minimal interlaminar fenestration or a translaminar
approach. If intradiscal material had to be removed, a limited
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nucleotomy was also performed [15]. In case of a lateral lum-
bar herniation, a lateral extraforaminal approach was per-
formed [16]. Right after the extraction of the disk tissue, it
was transferred into a sterile transport vial and provided to
TETEC AG for the GMP compliant manufacturing of the
investigational medicinal product NDisc plus.
Transplantation
Transp l an t a t i on was pe r fo rmed 90 days a f t e r
sequestrectomy. NDplus or NDbasic was applied via an
injection with a dual-needle technique directly at the
intended site of action. NDplus or NDbasic is to be
transplanted in a comfortable lateral or abdominal posi-
tion. After the treatment level is localized and local anes-
thesia is applied, the puncture of the intervertebral disk
was taken contra-laterally to the side of the disk surgery.
An injection needle was placed in the center of the disk
space under image guidance and the medicinal product
was injected. In case of an ADD, the same procedure
described above was conducted additionally at the adja-
cent, proximally located disk. Positioning of the needles
and the mandarin took place simultaneously to minimize
radiation exposure [14].
Statistical analysis
This is a non-confirmatory study without pre-specified
decision-making rules or hypotheses. Except laboratory
values, all statistical analyses are descriptive and explor-
atory and there was no adjustment of significance levels
for multiple testing or interim analyses. For laboratory
values, the Kolmogorov-Smirnov test was used for testing
normal distribution. The unpaired Student’s t test, Mann-
Whitney U test and Fisher’s exact test were used to ana-
lyze differences in laboratory values as applicable. A P
value <0.05 was considered statistically significant. For
CRP, values below detection levels (<0.02 mg/dL) were
set to 0.02 and for IL-6, values below detection levels
(<2.0 pg/mL) were set to 2.0. All values were expressed
as mean ± SD. All results were presented by treatment
group (NDplus and NDbasic). All data were pooled across
study centers for analysis and safety evaluations for all
subgroups or categories were also performed by pooling
ADD and HD patients. Figures were designed using
GraphPad Prism (version 5.0 for Mac OS X, GraphPad
Software, La Jolla California USA, www.graphpad.com).
Results
The demographic details and preoperative characteristics
of the patients are presented in Table 2. Twenty-four
patients with single lumbar disk herniation were prospec-
tively included in the study (Fig. 1). The proximally lo-
cated disk was also degenerated in seven patients. The
most commonly affected level of disk herniation was at
L5/S1 in both groups. Twenty of the 24 patients were
treated, 12 patients with the IMP NDisc plus (patients
with ADD: two) and eight patients with the control prep-
aration NDisc basic (patients with ADD: three). Four pa-
tients were excluded from the clinical trial before trans-
plantation due to subsequently detected exclusion criteria,
or, at their own request.
The mean volume of injection was 1.19 mL.
Eight patients (n = 6 in the NDplus and n = 2 in the
NDbasic group) experienced TEAEs, all of which were of
mild or moderate intensity. Only two patients had TEAEs
that were assessed by the investigator as related to the
medical intervention or to either of the study treatment.
One patient of the NDisc basic group experienced spinal
pain 21 days post implant (non serious TEAE) assessed as
related to both surgery and study treatment. One patient of
the NDisc plus experienced an intevertebral disk protru-
sion (serious TEAE) assessed also as related to both sur-
gery and study treatment. The patient underwent further
surgery. No further spinal complications occurred in phase
I. Considering the small number of patients with ADD, no
differences were apparent between patients with and with-
out ADD with respect to TEAEs and inflammatory pa-
rameters. The most commonly occurring TEAE was
nasopharyngitis in three patients in the NDplus group
and this was not related to the sequestrectomy or IMP.
Laboratory parameters in both treatment groups increased
temporarily after 36 h of sequestrectomy (CRP: NDplus group
3.0 ± 3 mg/dL vs. NDbasic group 3.0 ± 4 mg/dL; IL-6:
NDplus group 10.7 ± 6 pg/mL and NDbasic group
12.0 ± 13 pg/mL) and turned to normal thereafter. CRP did
not change after implantation, whereas IL-6 showed minor
changes with a peak at 42 h post implantation. In the
NDplus cohort IL-6 was elevated over a broader range, but
this was not statistically significant (p > 0.05) (Fig. 2).
Post implantation there were no relevant changes in systol-
ic and diastolic blood pressure and pulse rate from base line.
In the MRI, extradiscal fluid collection (EDFC) was
observed in three patients (n = 2/12 in the NDplus group
vs. n = 1/8 in the NDbasic group) after the implantation,
but did not have any space-occupying effect (see Fig. 3): in
one patient in each group at 48 h and in two patients in the
NDplus group at 21 days after transplantation. One of these
patients demonstrated a recurrent disk herniation, which
later also required surgery (7 months postoperative).
No fractures or more than moderate degenerative foraminal
stenosis and degenerative spinal stenosis were observed.
Osteochondrosis assessed by Modic grading of MRIs did
not appear to worsen in any of the disk types during Phase I.
Neurosurg Rev (2017) 40:155–162 159
Discussion
We have described the safety results of the first randomized
prospective clinical study for ADCT in the treatment of surgi-
cally treated lumbar disks and in degenerated adjacent. The
goal of ADCT is to reduce the degenerative sequel after lum-
bar disk surgery or to prophylactically avoid degeneration in
adjacent disks. Injection of material in the disk, however,
theoretically carries several risks such as extrusion of the
injected material, increased intradiscal pressure potentially
provoking disk herniations, and local or systemic inflamma-
tory reactions.
Current treatment strategies for IVDD are aggressive
surgical removal of the pathological disk or spondylodesis
that do not address options of restoring structural or bio-
logical deteriorations of the IVD as the underlying prob-
lem. The rate of lumbar fusion surgery is rising dramati-
cally compared to other musculoskeletal surgical proce-
dures [17]. Patient self-rating for unsuccessful treatment
after fusions for degenerative conditions ranges from 30
to 40 % [18]. Moreover, major complication rates of up to
20 % and long-term consequences of spinal fusion like
adjacent segment degeneration of 37 % within 10 years
have to be kept in mind [2]. Thus, lumbar fusion does not
sufficiently improve the patient’s condition in many ways.
Better outcomes were expected by substantially reducing
the tissue damage with the introduction of minimal inva-
sive spine surgery [3, 4]. Nevertheless, ADCT may offer a
less invasive, biological alternative to lumbar fusion in an
attempt to address LBP associated with IVDD earlier in
the degenerative cascade.
Surgical interventions entail physiological responses
including the rise of inflammatory cytokines [19].
Additionally, the reintroduction of disk cells to initiate








Mean age in years (SD) 44.7 (6.7) 40.4 (9.8)
Sex Female n (%) 2/12 (16.6) 8/12 (66.6)
Male n (%) 10/12 (83.3) 4/12 (33.3)
Tobacco use No n (%) 7/12 (58.3) 8/12 (66.6)
Yes n (%) 5/12 (41.6) 4/12 (33.3)
Work status Working full-time n (%) 10/12 (83.3) 9/12 (75.0)
Working part-time n (%) 1/12 (8.3) 2/12 (16.6)
Unemployed n (%) 1/12 (8.3) 0/12 (0.0)
Not employed (e.g., homemaker, student) n (%) 0/12 (0.0) 1/12 (8.3)
Retired n (%) 0/12 (0.0) 0/12 (0.0)
BMI (kg/m2) 24.2 (2.2) 24.9 (2.8)
Adjacent level degeneration Presence of adjacent degenerative disc n (%) 2/12 (16.6) 5/12 (41.6)
Absence of adjacent degenerative disc n (%) 10/12 (83.3) 7/12 (58.3)
Location of disc herniation Between vertebra L3 and L4 n (%) 1/12 (8.3) 0/12 (0.0)
Between vertebra L4 and L5 n (%) 3/12 (25.0) 3/12 (25.0)
Between vertebra L5 and S1 n (%) 8/12 (66.6) 9/12 (75.0)
Prior analgesic medication Subjects with prior analgesic medication 10/12 (83 %) 11/12 (91.7)
Opioids, metamizole, paracetamol 5/12 (41.6) 6/12 (50)
Non-steroidal anti-inflammatory drugs
(e.g., diclofenac, naproxen)
6/12 (50.0) 11/12 (91.7)
BMI body mass index, n number of patients, SD standard deviation
Fig. 1 Twenty-four patients with single lumbar disc herniation were
prospectively included in the study
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immune system and potentially even specific immune re-
sponses. Therefore, observation of a pro-inflammatory re-
sponse gives an early warning of potential complications
like an autoimmune response against the implanted bio-
material. CRP is a long-term clinical standard to monitor
innate responses and is independent of pain management
strategies [19]. Among other pro-inflammatory cytokines,
IL-6 may be regarded as an important component contrib-
uting to the local inflammatory process in disk herniations
[20]. Moreover, serum levels of IL-6 may be increased in
patients with lumbar radicular pain due to disk herniation
[21]. There is no data in the literature, which role serum
IL-6 plays after lumbar sequestrectomy. In our study pop-
ulation, CRP and IL-6 were evaluated 36 h after surgery.
Furthermore, IL-6 increased 42 h after implantation, but
turned to normal values thereafter. Thus, there is no indi-
cation of relevant immunological consequences of the
intradiscal injection at short-term follow-up, neither in
the NDisc plus nor in the NDisc basic cohort.
Routine treatment (elective sequestrectomy) in the target
patient population was considered to be associated with AEs
such as recurrent disk herniation or ongoing or recurrent low
back pain or sciatica in up to 25 % of patients within 2 years.
Symptomatic reherniations occur in approximately 10 % of
patients with the highest risk within the first 6 months [15].
Recurrent symptoms due to disk degeneration or
osteochondrosis also termed post-discectomy syndrome may
occur over time [22]. In the present Phase I study, there was
one reherniation requiring reoperation early after
sequestrectomy and before implantation was scheduled,
which is clearly unrelated to the injection substrate. Thus, no
indication for an increased risk of reherniations due to the
injected biomaterial was observed.
Early postoperative routineMRI is difficult to interpret due to
postoperative changes. It is well known, that (residual) interver-
tebral disk protrusions are common on MRI after
sequestrectomy [23]. It is therefore questionable if MRI in the
early postoperative period after lumbar surgery is meaningful.
Early postoperativeMRI must be interpreted with caution, since
correlation between clinical and radiological findings is weak
[24]. TheMRI data in Phase I revealed aminimal EDFC in three
patients. This may also occur after routine disk surgery. As
previously described, in one case of EDFC, a patient developed
a disk reherniation after transplantation, which required surgery
7months after the index operation. Nonetheless, given EDFC as
a common finding after disk surgery it is doubtful that the find-
ing of small EDFC represents an elevated risk of reherniation.
Overall conclusions
Overall, the rates of radiological and clinical reherniations as
well as of AEs in Phase I of this trial are comparable with
those expected in the early time course after elective disk
surgery. No indications of harmful material extrusion or im-
munological consequences due to the IMP NDplus were ob-
served. Therefore, the study appears to be safe and feasible.
Fig. 2 Laboratory values. SE sequestrectomy, IMP implantation
Fig. 3 Post-transplant T2-weighted MRI. An extradiscal fluid collection
(➔) was observed in three patients after transplantation surgery
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Safety analyses of Phase I of this trial indicate a relatively low
risk considering the benefits that patients with debilitating
degenerative disk disease may gain. Regardless of the prom-
ising results of this Phase I study, further analyses are neces-
sary and warranted.
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